RxDoctor Payments Data

Moiz Tajkhanji, MD

Family Medicine · Live Oak, TXNPI 1215022421

Payments from drug & device makers

$4,875in general payments, 2019–2025

Across 230 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$422
  • Bayer$397
  • GSK$256
  • Lilly USA, LLC$248
  • AbbVie$232
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,80098%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,875 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$147,582
Medicare patients
380
Services billed
3,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide225$258,232
MounjaroTirzepatide97$104,646
JardianceEmpagliflozin58$73,382
TrulicityDulaglutide44$68,280
EliquisApixaban43$68,155
MyrbetriqMirabegron46$38,475
FarxigaDapagliflozin Propanediol25$32,851
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$29,195
Tresiba Flextouch U-100Insulin Degludec35$26,797
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$18,420
JanuviaSitagliptin Phosphate11$17,771
TradjentaLinagliptin12$15,245
SymbicortBudesonide/Formoterol Fumarate41$13,520
Synjardy XrEmpagliflozin/Metformin Hcl21$12,119
Victoza 3-PakLiraglutide11$11,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$422$258,232225 claims
Lilly USA, LLCMounjaro, Trulicity$248$172,926141 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Stiolto Respimat, Spiriva Respimat$87$118,780118 claims
PfizerEliquis$198$68,15543 claims
AstraZenecaFarxiga, Symbicort$1,168$46,37166 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$256$43,39057 claims
Astellas Pharma US IncMyrbetriq$201$38,47546 claims
MerckJanuvia$36$17,77111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Live Oak

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →